These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 10868297)

  • 21. CD28 engagement by B7/BB-1 induces transient down-regulation of CD28 synthesis and prolonged unresponsiveness to CD28 signaling.
    Linsley PS; Bradshaw J; Urnes M; Grosmaire L; Ledbetter JA
    J Immunol; 1993 Apr; 150(8 Pt 1):3161-9. PubMed ID: 7682233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IFN-gamma-activated primary murine astrocytes express B7 costimulatory molecules and prime naive antigen-specific T cells.
    Nikcevich KM; Gordon KB; Tan L; Hurst SD; Kroepfl JF; Gardinier M; Barrett TA; Miller SD
    J Immunol; 1997 Jan; 158(2):614-21. PubMed ID: 8992975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular and molecular characterization of the scurfy mouse mutant.
    Clark LB; Appleby MW; Brunkow ME; Wilkinson JE; Ziegler SF; Ramsdell F
    J Immunol; 1999 Mar; 162(5):2546-54. PubMed ID: 10072494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antigen-experienced T cells undergo a transient phase of unresponsiveness following optimal stimulation.
    De Mattia F; Chomez S; Van Laethem F; Moulin V; Urbain J; Moser M; Leo O; Andris F
    J Immunol; 1999 Dec; 163(11):5929-36. PubMed ID: 10570279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression.
    Chuang E; Alegre ML; Duckett CS; Noel PJ; Vander Heiden MG; Thompson CB
    J Immunol; 1997 Jul; 159(1):144-51. PubMed ID: 9200449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T:T antigen presentation by activated murine CD8+ T cells induces anergy and apoptosis.
    Chai JG; Bartok I; Scott D; Dyson J; Lechler R
    J Immunol; 1998 Apr; 160(8):3655-65. PubMed ID: 9558065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is CTLA-4 a master switch for peripheral T cell tolerance?
    Bluestone JA
    J Immunol; 1997 Mar; 158(5):1989-93. PubMed ID: 9036940
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A mutant B7-1/Ig fusion protein that selectively binds to CTLA-4 ameliorates anti-tumor DNA vaccination and counters regulatory T cell activity.
    Chakrabarti R; Zhou ZF; Chang Y; Prud'homme GJ
    Vaccine; 2005 Aug; 23(37):4553-64. PubMed ID: 15919138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CTLA-4-Mediated inhibition of early events of T cell proliferation.
    Brunner MC; Chambers CA; Chan FK; Hanke J; Winoto A; Allison JP
    J Immunol; 1999 May; 162(10):5813-20. PubMed ID: 10229815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T-cell regulation by CD28 and CTLA-4.
    Alegre ML; Frauwirth KA; Thompson CB
    Nat Rev Immunol; 2001 Dec; 1(3):220-8. PubMed ID: 11905831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.
    Yang YF; Zou JP; Mu J; Wijesuriya R; Ono S; Walunas T; Bluestone J; Fujiwara H; Hamaoka T
    Cancer Res; 1997 Sep; 57(18):4036-41. PubMed ID: 9307290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human CTLA-4 is expressed in situ on T lymphocytes in germinal centers, in cutaneous graft-versus-host disease, and in Hodgkin's disease.
    Vandenborre K; Delabie J; Boogaerts MA; De Vos R; Lorré K; De Wolf-Peeters C; Vandenberghe P
    Am J Pathol; 1998 Apr; 152(4):963-73. PubMed ID: 9546357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CTLA-4: new insights into its biological function and use in tumor immunotherapy.
    Egen JG; Kuhns MS; Allison JP
    Nat Immunol; 2002 Jul; 3(7):611-8. PubMed ID: 12087419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autoantibodies to CTLA-4 enhance T cell proliferation.
    Matsui T; Nishioka K; Kato T; Yamamoto K
    J Rheumatol; 2001 Jan; 28(1):220-1. PubMed ID: 11196536
    [No Abstract]   [Full Text] [Related]  

  • 35. CTLA-4: a key regulatory point in the control of autoimmune disease.
    Scalapino KJ; Daikh DI
    Immunol Rev; 2008 Jun; 223():143-55. PubMed ID: 18613834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of cytotoxic T lymphocyte antigen 4 (CTLA-4) restricts clonal expansion of helper T cells.
    Doyle AM; Mullen AC; Villarino AV; Hutchins AS; High FA; Lee HW; Thompson CB; Reiner SL
    J Exp Med; 2001 Oct; 194(7):893-902. PubMed ID: 11581312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low concentrations of lipopolysaccharide synergize with peptides to augment human T-cell proliferation and can prevent the induction of non-responsiveness by CTLA4-Ig.
    Goodier MR; Londei M
    Immunology; 2001 Jan; 102(1):15-23. PubMed ID: 11168632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The contributions of T-cell anergy to peripheral T-cell tolerance.
    Lechler R; Chai JG; Marelli-Berg F; Lombardi G
    Immunology; 2001 Jul; 103(3):262-9. PubMed ID: 11454055
    [No Abstract]   [Full Text] [Related]  

  • 39. The role of CTLA-4 in immune regulation.
    Verhagen J; Sabatos CA; Wraith DC
    Immunol Lett; 2008 Jan; 115(1):73-4. PubMed ID: 18035425
    [No Abstract]   [Full Text] [Related]  

  • 40. Expression of CTLA-4 in nonhuman primate lymphocytes and its use as a potential target for specific immunotoxin-mediated apoptosis: results of in vitro studies.
    Palmisano GL; Tazzari PL; Cozzi E; Bolognesi A; Polito L; Seveso M; Ancona E; Ricci F; Conte R; Stirpe F; Ferrara GB; Pistillo MP
    Clin Exp Immunol; 2004 Feb; 135(2):259-66. PubMed ID: 14738454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.